Selecta Biosciences logo
VerifiedBiotechnology Research

Selecta Biosciences

In November 2023, Selecta Biosciences Inc.(NASDAQ: SELB) merged with Cartesian Therapeutics to create a publicly traded company pioneering RNA cell therapy to treat autoimmune disease. The combined company will focus on advancing Cartesian’s wholly owned pipeline, including Descartes-08, Cartesian’s clinical-stage lead product candidate being evaluated in patients with myasthenia gravis and other autoimmune diseases. For more information about the company and updates, please visit or follow us on LinkedIn @Cartesian-Therapeutics.

7-day free trial · no credit card

HeadquartersWatertown, United StatesEmployees11(51 to 200)Annual revenue$100M to <$1BWebsiteselectabio.comLinkedIn profileLinkedIn

Verified contacts

15

available on Kipplo

LinkedIn employees

11

51 to 200 range

Open roles

no listings

Distinct roles

11

indexed titles

Tech stack

3

tools in use

Monthly traffic

886

organic / mo

Sign up free to see all 15 verified contacts at Selecta Biosciences

Free for 7 days · 50 credits · no card · only pay for verified records.

Sign up free

Decision-makers and verified team members

15 contacts with verified email or phone · masked until revealed.

Sign up free →

Top roles at Selecta Biosciences

11 distinct titles indexed · top 10 shown.

  • 2()
  • 1accounts payable specialist
  • 1finance accounting manager
  • 1people and culture intern
  • 1preclinical safety lead
  • 1quality manager gxp
  • 1scientist
  • 1sec reporting manager
  • 1senior director, cmc-ra
  • 1vice president, regulatory affairs
  • +1more titles

Sign up to unlock all 15 contacts at Selecta Biosciences

Free for 7 days · 50 credits · no card · only pay for verified records.

Sign up free

Sign up to reveal 15 verified contacts at Selecta Biosciences

7-day trial · no credit card · cancel anytime · only pay for verified records.

Trusted by sales, marketing, and GTM engineering teams.

Selecta Biosciences | Kipplo Discover